KR20140053419A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR20140053419A
KR20140053419A KR1020147010618A KR20147010618A KR20140053419A KR 20140053419 A KR20140053419 A KR 20140053419A KR 1020147010618 A KR1020147010618 A KR 1020147010618A KR 20147010618 A KR20147010618 A KR 20147010618A KR 20140053419 A KR20140053419 A KR 20140053419A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
tablet
minutes
composition
calcitonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147010618A
Other languages
English (en)
Korean (ko)
Inventor
모이스 아즈리아
사이먼 데이비드 베이트먼
아나수야 아쇼크 고쉬
서우펑 리
앨런 에드워드 로이스
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140053419A publication Critical patent/KR20140053419A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147010618A 2005-11-17 2006-11-16 약제학적 조성물 Ceased KR20140053419A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73763105P 2005-11-17 2005-11-17
US60/737,631 2005-11-17
PCT/US2006/044642 WO2007061829A2 (en) 2005-11-17 2006-11-16 Pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011726A Division KR101432313B1 (ko) 2005-11-17 2006-11-16 약제학적 조성물

Publications (1)

Publication Number Publication Date
KR20140053419A true KR20140053419A (ko) 2014-05-07

Family

ID=37875983

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147010618A Ceased KR20140053419A (ko) 2005-11-17 2006-11-16 약제학적 조성물
KR1020087011726A Expired - Fee Related KR101432313B1 (ko) 2005-11-17 2006-11-16 약제학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087011726A Expired - Fee Related KR101432313B1 (ko) 2005-11-17 2006-11-16 약제학적 조성물

Country Status (10)

Country Link
US (3) US20080255048A1 (OSRAM)
EP (1) EP1951207A2 (OSRAM)
JP (3) JP2009515993A (OSRAM)
KR (2) KR20140053419A (OSRAM)
CN (1) CN101309674A (OSRAM)
AU (1) AU2006318815B2 (OSRAM)
BR (1) BRPI0618723A2 (OSRAM)
CA (1) CA2626933C (OSRAM)
RU (1) RU2469709C2 (OSRAM)
WO (1) WO2007061829A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009515993A (ja) * 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
RS58636B1 (sr) 2012-03-22 2019-05-31 Novo Nordisk As Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
PL2827885T3 (pl) 2012-03-22 2019-01-31 Novo Nordisk A/S Kompozycje peptydów GLP-1 i ich otrzymywanie
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
WO2016128974A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents
WO2018033927A1 (en) * 2016-08-17 2018-02-22 Entera Bio Ltd. Formulations for oral administration of active agents
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US647A (en) 1838-03-21 Improved fishing-seine for deep water
US608618A (en) 1898-08-09 Thomas millen
US5866A (en) 1848-10-17 Dentist s deill
US536A (en) 1837-12-26 Beady binder for binding newspapers
US5773A (en) 1848-09-19 Sizing and drying cotton-batting
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JP2609022B2 (ja) * 1990-11-29 1997-05-14 北陸製薬株式会社 ポリカルボフィルカルシウム含有製剤
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
EA000361B1 (ru) * 1995-02-08 1999-06-24 Яманучи Юроп Б.В. Способ приготовления гранулята, содержащего активный при пероральном введении бета-лактамный антибиотик
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
WO2002018330A1 (en) 2000-08-29 2002-03-07 Nobex Corporation 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
ES2282436T3 (es) * 2001-06-01 2007-10-16 Novartis Ag Administracion oral de hormona paratiroide y calcitonina.
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
CA2498410A1 (en) * 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
EP1643978A1 (en) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
BRPI0412265A (pt) 2003-07-23 2006-09-05 Novartis Ag uso de calcitonina em osteoartrite
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
JP2009515993A (ja) * 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物

Also Published As

Publication number Publication date
BRPI0618723A2 (pt) 2011-09-06
US9622975B2 (en) 2017-04-18
CA2626933C (en) 2015-12-29
JP2012211159A (ja) 2012-11-01
WO2007061829A2 (en) 2007-05-31
US20110218148A1 (en) 2011-09-08
CA2626933A1 (en) 2007-05-31
KR20080066958A (ko) 2008-07-17
JP6147290B2 (ja) 2017-06-14
JP6049317B2 (ja) 2016-12-21
KR101432313B1 (ko) 2014-08-20
AU2006318815B2 (en) 2010-08-19
EP1951207A2 (en) 2008-08-06
WO2007061829A3 (en) 2007-08-30
US20080255048A1 (en) 2008-10-16
CN101309674A (zh) 2008-11-19
JP2015145410A (ja) 2015-08-13
RU2469709C2 (ru) 2012-12-20
RU2008123380A (ru) 2009-12-27
AU2006318815A1 (en) 2007-05-31
JP2009515993A (ja) 2009-04-16
US20150250729A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
US9622975B2 (en) Pharmaceutical composition
AU2008202879B2 (en) Use of calcitonin in osteoarthritis
EP1945243B1 (en) Use of calcitonin for the treatment of ra
MX2008006319A (en) Pharmaceutical composition
HK1152229B (en) Use of calcitonin in osteoarthritis
HK1089935B (en) Use of calcitonin in osteoarthritis

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140421

Application number text: 1020087011726

Filing date: 20080516

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140812

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150107

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140812

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I